发布求助
文献互助 智能选刊 最新文献

Clinical calcium最新文献

筛选
英文 中文
[Wnt signaling and bone metabolic diseases.] [Wnt信号与骨代谢疾病]
Clinical calcium Pub Date : 2019-01-01 DOI: 10.20837/4201903329
Mika Yamauchi, Toshitsugu Sugimoto
{"title":"[Wnt signaling and bone metabolic diseases.]","authors":"Mika Yamauchi,&nbsp;Toshitsugu Sugimoto","doi":"10.20837/4201903329","DOIUrl":"https://doi.org/10.20837/4201903329","url":null,"abstract":"<p><p>Wnt signaling is known to be involved in metabolic bone disorders. Serum levels of sclerostin, a bone-specific protein that inhibits Wnt signaling, have been investigated in a variety of metabolic bone disorders. Serum sclerostin levels are positively correlated with bone mineral density in patients with osteoporosis. Elderly women with high serum sclerostin levels, however, are at increased risk of bone fractures. Since serum sclerostin levels are low in primary hyperparathyroidism and high in hypoparathyroidism, parathyroid hormone could be classified as a factor that regulates sclerostin levels. Serum sclerostin levels are high in glucocorticoid-induced osteoporosis and diabetes mellitus, which feature reduced bone formation. Finally, serum sclerostin levels increase with decreasing renal function. These findings highlight the potential of serum sclerostin levels as a new index for bone assessments which are different in nature from bone mineral density and bone metabolic markers.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 3","pages":"329-336"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37007577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Sequential treatment of osteoporosis with anti-sclerostin.] 抗硬化素序贯治疗骨质疏松症
Clinical calcium Pub Date : 2019-01-01 DOI: 10.20837/4201903363
Daisuke Inoue
{"title":"[Sequential treatment of osteoporosis with anti-sclerostin.]","authors":"Daisuke Inoue","doi":"10.20837/4201903363","DOIUrl":"https://doi.org/10.20837/4201903363","url":null,"abstract":"<p><p>Romosozumab is a humanized anti-sclerostin monoclonal antibody that has just been approved for the treatment of osteoporosis in Japan. Romosozumab causes both transient stimulation of bone formation and continuous suppression of resorption, thereby increasing bone mineral density and decreasing fracture incidence. Because the effect of romosozumab is reversible, sequential therapy with anti-resorptives after romosozumab will be necessary. This overview summarizes the results of ARCH study demonstrating superior efficacy of romosozumab compared to alendronate and effect of sequential therapy with alendronate. Possible adverse effect of romosozumab on cardiovascular diseases will also be discussed.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 3","pages":"363-369"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37181632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
[Regulations of osteoclast formation and function by Wnt signals.] [Wnt信号对破骨细胞形成和功能的调控]
Clinical calcium Pub Date : 2019-01-01 DOI: 10.20837/4201903309
Yasuhiro Kobayashi, Shunsuke Uehara, Masanori Koide
{"title":"[Regulations of osteoclast formation and function by Wnt signals.]","authors":"Yasuhiro Kobayashi,&nbsp;Shunsuke Uehara,&nbsp;Masanori Koide","doi":"10.20837/4201903309","DOIUrl":"https://doi.org/10.20837/4201903309","url":null,"abstract":"<p><p>Wnt ligands activate β-catenin-dependent canonical and -independent non-canonical signaling pathways. Recent studies established importance of Wnt/β-catenin signaling in bone accrual. Antibodies against the Wnt inhibitor sclerostin and those against the Wnt inhibitor Dickkopf-1 have been shown to be effective for increasing bone mass. In addition to their effects on bone formation, roles of Wnt signals in bone resorption are gradually clarified. In this review, we would like to introduce recent advances in roles of Wnt signals in osteoclast formation and functions and regulation of sclerostin expression by osteoclasts.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 3","pages":"309-315"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37007573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Osteocytes and Wnt signaling.] [骨细胞和Wnt信号]
Clinical calcium Pub Date : 2019-01-01 DOI: 10.20837/4201903317
Seiji Fukumoto
{"title":"[Osteocytes and Wnt signaling.]","authors":"Seiji Fukumoto","doi":"10.20837/4201903317","DOIUrl":"https://doi.org/10.20837/4201903317","url":null,"abstract":"<p><p>Osteocytes has many functions such as sensing mechanical stress to bone, regulating formation and activity of osteoclasts as well as modulation of bone metabolism and function of other organs through production of humoral factors such as sclerostin and FGF23. Sclerostin suppresses bone formation and stimulate bone resorption by inhibiting Wnt activity. FGF23 regulates phosphate metabolism mainly acting on kidney. In contrast, it is also reported that sclerostin works in kidney and FGF23 inhibits Wnt activity in osteoblasts. However, the physiological significance of these actions of sclerostin and FGF23 needs to be established by future investigations.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 3","pages":"317-321"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37007574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[ASBMR 2018 report on basic research.] [ASBMR 2018年基础研究报告]
Clinical calcium Pub Date : 2019-01-01 DOI: CliCa190199103
Yuuki Imai
{"title":"[ASBMR 2018 report on basic research.]","authors":"Yuuki Imai","doi":"CliCa190199103","DOIUrl":"https://doi.org/CliCa190199103","url":null,"abstract":"<p><p>This is a brief report on ASBMR 2018 held at Montreal, Quebec, Canada, focusing on basic research. Topics of ASBMR 2018 were varied among wide research fields, however, this report focuses on several topics because of spatio-temporal restriction of attendees. Also, the selected topics were very limited according to the author's interests.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"99-103"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36808016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[ASBMR topics from clinical research(osteoporosis and sarcopenia).] [来自临床研究的ASBMR主题(骨质疏松症和肌肉减少症)]
Clinical calcium Pub Date : 2019-01-01 DOI: CliCa1901112115
Ken-Ichiro Tanaka
{"title":"[ASBMR topics from clinical research(osteoporosis and sarcopenia).]","authors":"Ken-Ichiro Tanaka","doi":"CliCa1901112115","DOIUrl":"https://doi.org/CliCa1901112115","url":null,"abstract":"<p><p>There are a lot of progressive topics about osteoporosis and sarcopenia in 2018 ASBMR Annual Meeting, involving an association between diabetes and bone microarchitecture, associations between atypical femoral fractures and bisphosphonate drug holidays as well as pre-treatment bone mineral density, an effect of combined denosumab and high-dose teriparatide on bone parameters, and relationships between muscle and deuterated creatine, a selective androgen receptor modulator, and high-dose vitamin D supplementation.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"112-115"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36808019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[ASBMR Topics from clinical research concerning bone and mineral metabolism other than osteoporosis.] [ASBMR除骨质疏松症外有关骨和矿物质代谢的临床研究主题]
Clinical calcium Pub Date : 2019-01-01 DOI: CliCa1901116120
Yuichi Takashi
{"title":"[ASBMR Topics from clinical research concerning bone and mineral metabolism other than osteoporosis.]","authors":"Yuichi Takashi","doi":"CliCa1901116120","DOIUrl":"https://doi.org/CliCa1901116120","url":null,"abstract":"<p><p>This is a brief report summarizing topics in ASBMR 2018 held at Montreal, Canada in September 28th to October 1st, 2018. In this report, I would like to introduce several topics from clinical research concerning bone and mineral metabolism other than osteoporosis. One of the topics in this area is the progress of research and development of drugs for rare skeletal diseases, which have been considered to be difficult to treat. Especially, there were many abstracts concerning burosumab, which is a new therapeutic medicine for FGF23-related hypophosphatemic rickets/osteomalacia. In addition, I will focus on the papers concerning muscle, osteocalcin, vitamin D and microbiota.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"116-120"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36808020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Drugs for osteoporosis.] [治疗骨质疏松的药物。]
Clinical calcium Pub Date : 2018-01-01 DOI: CliCa1801114116
Seiji Fukumoto
{"title":"[Drugs for osteoporosis.]","authors":"Seiji Fukumoto","doi":"CliCa1801114116","DOIUrl":"https://doi.org/CliCa1801114116","url":null,"abstract":"<p><p>Many important results concerning several drugs for osteoporosis have been presented in ASBMR 2017 meeting. Longer use of denosumab for up to 10 years was shown to induce lower risk of fractures. In addition, antiresorptives were shown to be useful after abaloparatide or romosozumab. Now that several important drugs have been already developed for osteoporosis, research and drug development for other musculoskeletal organs than bone are necessary.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"28 1","pages":"114-116"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35689607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cellular metabolite controls oxidative stress resistance.] [细胞代谢物控制氧化应激抵抗。]
Clinical calcium Pub Date : 2018-01-01 DOI: CliCa18013944
Tadahiro Shimazu
{"title":"[Cellular metabolite controls oxidative stress resistance.]","authors":"Tadahiro Shimazu","doi":"CliCa18013944","DOIUrl":"https://doi.org/CliCa18013944","url":null,"abstract":"<p><p>Cellular metabolites such as acetylcoenzyme A and nicotinamide adenine dinucleotide control gene transcription via modulating the reader or eraser protein in histone modification. A ketone body, D-β-hydroxybutyrate is an endogenous metabolite which has been reported as a class Ⅰ histone deacetylases(HDACs). In this chapter, a molecular basis of the ketone body in transcriptional control and protection against oxidative stress is reviewed and discussed.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"28 1","pages":"39-44"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35689711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intravital bone imaging:osteoclast.] [活体骨成像:破骨细胞。]
Clinical calcium Pub Date : 2018-01-01 DOI: CliCa1802211216
Junichi Kikuta, Masaru Ishii
{"title":"[Intravital bone imaging:osteoclast.]","authors":"Junichi Kikuta,&nbsp;Masaru Ishii","doi":"CliCa1802211216","DOIUrl":"https://doi.org/CliCa1802211216","url":null,"abstract":"<p><p>Osteoclasts are bone-resorbing giant polykaryons that differentiate from mononuclear macrophage/monocyte-lineage hematopoietic precursors. We have originally established an advanced imaging system for visualizing the in vivo behavior of mature osteoclasts in living bone tissues with intravital multiphoton microscopy. By means of this system, we could grasp the real time-course of osteoclastic bone resorption, and identified two distinct functional states of differentiated osteoclasts, 'bone-resorptive' and 'non-resorptive'. Intravital imaging also revealed that various biologic drugs acted directly on mature osteoclasts during inflammatory bone destruction. In this review, we show the latest data of intravital imaging of osteoclast dynamics.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"28 2","pages":"211-216"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35767321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信